Literature DB >> 9788972

Antibacterial activity of human neutrophil defensins in experimental infections in mice is accompanied by increased leukocyte accumulation.

M M Welling1, P S Hiemstra, M T van den Barselaar, A Paulusma-Annema, P H Nibbering, E K Pauwels, W Calame.   

Abstract

Neutrophil defensins (or human neutrophil peptides-HNP) are major constituents of the azurophilic granules of human neutrophils and have been shown to display broad-spectrum antimicrobial activity. Other activities of these defensins, which are released from stimulated neutrophils, include cytotoxic, stimulatory, and chemotactic activities toward a variety of target cells. We studied the potential use of HNP-1 for antibacterial therapy of experimental bacterial infections in mice. In experimental peritoneal Klebsiella pneumoniae infections in mice, HNP-1 injection was shown to markedly reduce bacterial numbers in the infected peritoneal cavity 24 h after infection. This antibacterial effect was found to be associated with an increased influx of macrophages, granulocytes, and lymphocytes into the peritoneal cavity. These leukocytes appeared to be a requirement for the antibacterial effect, since in leukocytopenic mice administration of HNP-1 did not display antibacterial activity. HNP-1 treatment also reduced bacterial numbers in experimental K. pneumoniae or Staphylococcus aureus thigh muscle infections. In this model, radiolabeled HNP-1 was found to accumulate at the site of infection, whereas most of the injected HNP-1 was rapidly removed from the circulation via renal excretion. These results demonstrate that neutrophil defensins display marked in vivo antibacterial activity in experimental infections in mice and that this activity appears to be mediated, at least in part, by local leukocyte accumulation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9788972      PMCID: PMC509009          DOI: 10.1172/JCI3664

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  24 in total

1.  Humoral regulation of monocytopoiesis during the early phase of an inflammatory reaction caused by particulate substances.

Authors:  D van Waarde; E Hulsing-Hesselink; L A Sandkuyl; R van Furth
Journal:  Blood       Date:  1977-07       Impact factor: 22.113

2.  The labeling of proteins and LDL with 99mTc: a new direct method employing KBH4 and stannous chloride.

Authors:  E K Pauwels; M M Welling; R I Feitsma; D E Atsma; W Nieuwenhuizen
Journal:  Nucl Med Biol       Date:  1993-10       Impact factor: 2.408

3.  Mouse neutrophils lack defensins.

Authors:  P B Eisenhauer; R I Lehrer
Journal:  Infect Immun       Date:  1992-08       Impact factor: 3.441

4.  Antibiotic therapy of infections due to Pseudomonas aeruginosa in normal and granulocytopenic mice: comparison of murine and human pharmacokinetics.

Authors:  A U Gerber; H P Brugger; C Feller; T Stritzko; B Stalder
Journal:  J Infect Dis       Date:  1986-01       Impact factor: 5.226

Review 5.  Defensins: antimicrobial and cytotoxic peptides of mammalian cells.

Authors:  R I Lehrer; A K Lichtenstein; T Ganz
Journal:  Annu Rev Immunol       Date:  1993       Impact factor: 28.527

6.  Plasma defensin concentrations are elevated in patients with septicemia or bacterial meningitis.

Authors:  A V Panyutich; E A Panyutich; V A Krapivin; E A Baturevich; T Ganz
Journal:  J Lab Clin Med       Date:  1993-08

7.  The modulation of IL-6 and TNF-alpha release by nitric oxide following stimulation of J774 cells with LPS and IFN-gamma.

Authors:  A M Deakin; A N Payne; B J Whittle; S Moncada
Journal:  Cytokine       Date:  1995-07       Impact factor: 3.861

8.  Defensins. Natural peptide antibiotics of human neutrophils.

Authors:  T Ganz; M E Selsted; D Szklarek; S S Harwig; K Daher; D F Bainton; R I Lehrer
Journal:  J Clin Invest       Date:  1985-10       Impact factor: 14.808

9.  Pulmonary deposition and disappearance of aerosolised secretory leucocyte protease inhibitor.

Authors:  J Stolk; J Camps; H I Feitsma; J Hermans; J H Dijkman; E K Pauwels
Journal:  Thorax       Date:  1995-06       Impact factor: 9.139

10.  Contribution of phagocytic cells and bacteria to the accumulation of technetium-99m labelled polyclonal human immunoglobulin at sites of inflammation.

Authors:  W Calame; M Welling; H I Feitsma; W T Goedemans; E K Pauwels
Journal:  Eur J Nucl Med       Date:  1995-07
View more
  36 in total

1.  Apoptosis of airway epithelial cells: human serum sensitive induction by the cathelicidin LL-37.

Authors:  Y Elaine Lau; Dawn M E Bowdish; Celine Cosseau; Robert E W Hancock; Donald J Davidson
Journal:  Am J Respir Cell Mol Biol       Date:  2005-12-09       Impact factor: 6.914

2.  The human cationic host defense peptide LL-37 mediates contrasting effects on apoptotic pathways in different primary cells of the innate immune system.

Authors:  Peter G Barlow; Yuexin Li; Thomas S Wilkinson; Dawn M E Bowdish; Y Elaine Lau; Celine Cosseau; Christopher Haslett; A John Simpson; Robert E W Hancock; Donald J Davidson
Journal:  J Leukoc Biol       Date:  2006-06-22       Impact factor: 4.962

3.  Histatin-derived monomeric and dimeric synthetic peptides show strong bactericidal activity towards multidrug-resistant Staphylococcus aureus in vivo.

Authors:  Mick M Welling; Carlo P J M Brouwer; Wim van 't Hof; Enno C I Veerman; Arie V Nieuw Amerongen
Journal:  Antimicrob Agents Chemother       Date:  2007-07-09       Impact factor: 5.191

Review 4.  Immune modulation by multifaceted cationic host defense (antimicrobial) peptides.

Authors:  Ashley L Hilchie; Kelli Wuerth; Robert E W Hancock
Journal:  Nat Chem Biol       Date:  2013-12       Impact factor: 15.040

5.  In vitro studies on the antimicrobial peptide human beta-defensin 9 (HBD9): signalling pathways and pathogen-related response (an American Ophthalmological Society thesis).

Authors:  Harminder S Dua; Ahmad Muneer Otri; Andrew Hopkinson; Imran Mohammed
Journal:  Trans Am Ophthalmol Soc       Date:  2014-07

6.  Cathelicidin administration protects mice from Bacillus anthracis spore challenge.

Authors:  Mark W Lisanby; Melissa K Swiecki; Brian L P Dizon; Kathryn J Pflughoeft; Theresa M Koehler; John F Kearney
Journal:  J Immunol       Date:  2008-10-01       Impact factor: 5.422

7.  The Staphylococcus aureus two-component regulatory system, GraRS, senses and confers resistance to selected cationic antimicrobial peptides.

Authors:  Soo-Jin Yang; Arnold S Bayer; Nagendra N Mishra; Michael Meehl; Nagender Ledala; Michael R Yeaman; Yan Q Xiong; Ambrose L Cheung
Journal:  Infect Immun       Date:  2011-10-10       Impact factor: 3.441

8.  Α-defensin expression of inflammatory response in open and laparoscopic colectomy for colorectal cancer.

Authors:  Konstantinos E Tsimogiannis; Konstantinos Telis; Alexandros Tselepis; George K Pappas-Gogos; Evangelos C Tsimoyiannis; George Basdanis
Journal:  World J Surg       Date:  2011-08       Impact factor: 3.352

9.  Concerns about (99m)Tc-labelled ciprofloxacin for infection detection.

Authors:  E K Pauwels; M M Welling; A Lupetti; A Paulusma-Annema; P H Nibbering; H S Balter
Journal:  Eur J Nucl Med       Date:  2000-12

10.  Antibacterial activity of human neutrophil defensin HNP-1 analogs without cysteines.

Authors:  Jobin Varkey; Ramakrishnan Nagaraj
Journal:  Antimicrob Agents Chemother       Date:  2005-11       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.